• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Bausch + Lomb Corporation

    5/21/25 4:36:14 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    8-K
    Bausch & Lomb Corp NYSE false 0001860742 0001860742 2025-05-21 2025-05-21
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    May 21, 2025

    Date of Report (Date of the earliest event reported)

     

     

    Bausch + Lomb Corporation

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Canada   001-41380   98-1613662

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

    520 Applewood Crescent

    Vaughan, Ontario

    Canada L4K 4B4

    (Address of Principal Executive Offices)(Zip Code)

    (905) 695-7700

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Shares, No Par Value   BLCO   New York Stock Exchange Toronto Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07. Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting of Shareholders of Bausch + Lomb Corporation (the “Company”) held on Wednesday, May 21, 2025, the shareholders of the Company voted on the following three proposals, each of which is described in detail in the Company’s Proxy Statement. The results are as follows:

    Proposal No. 1: Election of Directors. The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2026 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal:

     

         For    Against    Broker Non-Votes

    Nathalie Bernier

       337,617,248    1,924,336    8,383,437

    Gary Hu

       337,591,706    1,949,878    8,383,437

    Brett Icahn

       337,474,287    2,067,297    8,383,437

    Sarah B. Kavanagh

       337,602,211    1,939,373    8,383,437

    Karen L. Ling

       337,526,114    2,015,470    8,383,437

    John A. Paulson

       337,650,735    1,890,849    8,383,437

    Russel C. Robertson

       337,600,880    1,940,704    8,383,437

    Thomas W. Ross, Sr.

       337,583,018    1,958,566    8,383,437

    Brenton L. Saunders

       337,592,062    1,949,522    8,383,437

    Andrew C. von Eschenbach

       337,607,276    1,934,308    8,383,437

    Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Proxy Statement.

     

    For

      

    Against

      

    Abstain

      

    Broker Non-Votes

    326,901,905    11,592,430    1,047,249    8,383,437

    Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditor for the Company to hold office until the close of the 2026 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditor’s remuneration.

     

    For

      

    Withheld

    346,448,493    1,476,528


    Signatures

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    BAUSCH + LOMB CORPORATION

     

    By:  

    /s/ Robert D. Bailey

    Name:   A. Robert D. Bailey
    Title:   Executive Vice President and Chief Legal Officer

    Date: May 21, 2025

    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Surgical Bonnefoy Luc covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 73,383 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      6/16/25 4:46:45 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. was granted 20,338 shares, increasing direct ownership by 49% to 62,086 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:11:49 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Ross Thomas W. Sr. was granted 20,338 shares, increasing direct ownership by 51% to 60,391 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:10:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/27/25 8:16:24 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care